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Abstract
Background: Human embryonic stem cells (hESCs) are an attractive resource for new therapeutic approaches that involve
tissue regeneration. hESCs have exhibited low immunogenicity due to low levels of Mayor Histocompatibility Complex
(MHC) class-I and absence of MHC class-II expression. Nevertheless, the mechanisms regulating MHC expression in hESCs
had not been explored.
Methodology/Principal Findings: We analyzed the expression levels of classical and non-classical MHC class-I, MHC class-II
molecules, antigen-processing machinery (APM) components and NKG2D ligands (NKG2D-L) in hESCs, induced pluripotent
stem cells (iPSCs) and NTera2 (NT2) teratocarcinoma cell line. Epigenetic mechanisms involved in the regulation of these
genes were investigated by bisulfite sequencing and chromatin immunoprecipitation (ChIP) assays. We showed that low
levels of MHC class-I molecules were associated with absent or reduced expression of the transporter associated with
antigen processing 1 (TAP-1) and tapasin (TPN) components in hESCs and iPSCs, which are involved in the transport and
load of peptides. Furthermore, lack of b2-microglobulin (b2m) light chain in these cells limited the expression of MHC class I
trimeric molecule on the cell surface. NKG2D ligands (MICA, MICB) were observed in all pluripotent stem cells lines.
Epigenetic analysis showed that H3K9me3 repressed the TPN gene in undifferentiated cells whilst HLA-B and b2m acquired
the H3K4me3 modification during the differentiation to embryoid bodies (EBs). Absence of HLA-DR and HLA-G expression
was regulated by DNA methylation.
Conclusions/Significance: Our data provide fundamental evidence for the epigenetic control of MHC in hESCs and iPSCs.
Reduced MHC class I and class II expression in hESCs and iPSCs can limit their recognition by the immune response against
these cells. The knowledge of these mechanisms will further allow the development of strategies to induce tolerance and
improve stem cell allograft acceptance.
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Introduction
Human embryonic stem cells (hESCs) are pluripotent cells
derived from the inner cell mass of blastocysts. hESCs have the
capacity to differentiate into all tissues of the body, making them
useful in regenerative medicine. Nevertheless, elucidation of the
immunogenicity of hESCs-derived allografts, and their potential
rejection by the recipient remains elusive. Major histocompatibil-
ity complex (MHC) class I antigen processing and presentation is
required for effective T cell recognition and impacts graft
rejection. Early work showed that hESCs express very low levels
of MHC class I molecules on the cell surface and fail to elicit
immune responses in immune-competent mice [1], supporting the
hypothesis that these cells have immune-privilege properties which
expands their use in cell replacement therapy [2–5]. Several
reproductive and developmental tissues such as sperm, oocyte,
pre-implantation embryos and trophoblast cells show a reduced or
no expression of MHC class I as well as a lack of MHC class II
molecules. The lack of human lymphocyte antigen (HLA)-A, -B,
and MHC class II expression in trophoblast cells provide
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recognition [6]. Similarly, the loss of MHC class I expression in
tumour cells has allowed tumour survival and hindered the
rejection by host immune system [7,8]. Defects in the expression of
some components of the antigen processing machinery (APM),
such as transporter associated with antigen processing (TAP1/2),
low molecular mass protein (LMP2, LMP7) or tapasin (TPN)
genes have occurred at the epigenetic, transcriptional and
posttranscriptional level [9]. Additionally, a deficiency in some
proteins involved in MHC class I antigen processing and peptide
generation was reported in mesenchymal stem cells (MSCs) [10].
The non classical MHC class I molecules HLA-E, HLA-F and
HLA-G display a more restricted expression pattern and have
specialized immune regulatory functions. HLA-E exhibits leader
peptides derived from other HLA class I molecules and
predominantly inhibits NK (Natural Killer) cell functions. HLA-
G is mainly expressed in trophoblast cells and promotes tolerance
of the fetus by the maternal T and NK cells. Trophoblast cells
express HLA-G and –E which serves to prevent destruction by
maternal decidual NK cells [11,12]. Recently, it had been
reported that MSC secrete soluble HLA-G, inhibiting the lysis of
target cells by CTLs [13].
Although low MHC class I expression hinders recognition by T
and B cells, it may also lead to natural killer cell rejection of the
transplanted cells. Stimulatory NK cell receptors such as NKG2D
can recognize ligands (MICA, -B, ULBPs 1–5) expressed in
embryonic stem cells and lead to their elimination [14,15].
NKG2D is a potent stimulatory receptor which binds to a
family of ligands with structural homology to MHC class I proteins
[16]. Human ligands for NKG2D are not expressed in adult
healthy tissues but can be induced by cellular stress such as DNA
damage, inflammation, heat shock, viral infection or malignant
transformation [17,18].
The constitutive expression of MHC class II molecules is
restricted to antigen-presenting cells (APCs). Previous studies
showed that MHC class II gene expression is regulated by
epigenetic mechanisms. For example, the MHC class II transacti-
vator (CIITA) and the regulatory factor X (RFX) proteins serve as
focal points for recruiting histone modifying enzymes to MHC
class II promoters. CIITA itself is regulated by DNA methylation
and histone modifications [19,20].
Some soluble factors, such as TGF-b [21] and FasL [3] had
been proposed to inhibit immune responses by ESCs. Neverthe-
less, other reports showed that hESCs were rejected after
transplantation into wild-type, fully MHC-mismatched recipients
[22–24], indicating hESCs immunogenicity. Recently, Yachimo-
vich-Cohen et al [25] had demonstrated a new mechanism to
explain how hESCs avoid the allorecognition by the host immune
system. They attributed the hESCs inhibitory effect to the
L-arginine consumption by hESC arginase I, resulting in downreg-
ulation of the TCR CD3-f chain and T cell unresponsiveness.
Derivation of induced pluripotent stem cells (iPSCs) from adult
somatic cells has raised the possibility of their use for cell
replacement therapy and potentially avoiding immunological
rejection [26–28]. The knowledge of the molecular mechanisms
that regulates MHC expression on iPSCs may also have an impact
on potential use in transplant therapies.
In the present study, we hypothesized that the low expression of
MHC class I and absence of MHC class II in hESCs cells was
regulated through epigenetic mechanisms. DNA methylation and
histone modification analysis of genes involved in the antigen
processing pathway revealed a tight epigenetic control in hESCs.
Moreover, we demonstrated that MHC expression in iPSCs
behave in a similar way to hESCs.
Results
Low levels of MHC-I and absence of MHC-II expression in
Shef-1 and NTera2 cell lines
The expression of MHC class I and class II molecules was
analyzed in undifferentiated human embryonic stem cell line Shef-
1 and teratocarcioma cell line NT2 by real-time RT-PCR and
flow-cytometry. Both cell lines expressed low levels of MHC class I
and no expression of MHC class II on the cell surface (Figure 1A).
In agreement with these results, we observed low levels of mRNA
transcripts of classical HLA-I molecules (HLA-A and -B) and lack
of the non-classical molecules HLA-E, -F and –G in both cell lines
(Figure 1B). Moreover, the mRNA levels of b2-microglobulin
(b2m) were nearly undetected in Shef-1 cells but slightly enhanced
in NT2 cell line. Additionally, no expression of MHC class II
molecules was detected in stem cells.
To determine whether the reduced MHC class I expression
might reflect alterations in the antigen processing and presentation
in stem cells, we analyzed the expression of APM molecules by
real-time PCR. We used the PITOUT cell line, which express
MHC class I and class II molecules at high levels, as positive
control. Analysis of the APM components revealed that, the
transporter molecules TAP-1 and TAP-2 were absent or weakly
detected in Shef-1 and NT2 stem cell lines (Fig. 1B). hESC lacked
expression of Tapasin (TPN) and Calreticulin (CLR), which are
involved in the correct folding of MHC class I molecules, but these
molecules were detected at normal levels in the NT2 cell line.
Expression of the chaperone molecules, Calnexin (CNX) and
ERp57, and the immunoproteasome component LMP7 was
commonly detected in both cell lines and exhibited levels
comparable to the control cell line. In contrast, lack of the
expression of LMP2 was observed. The impaired constitutive
expression of MHC class I molecules in Shef-1 and NT2 cells
could be due to reduced transcription of some APM components.
Down-regulation of MHC expression in induced
pluripotent stem cells (iPSCs)
Although induced pluripotent stem cells have been proposed as
an alternative resource for tissue generation to minimize transplant
rejection, their immunological properties are at the moment
unknown. We analyzed the MHC expression in the induced
pluripotent stem cell line MSUH-002 and its parental human
fibroblasts IMR90.
The HLA class I and b2m mRNA levels were lower in iPSCs
than in parental fibroblast line (Figure 1C). HLA-B, -C, -E, and
b2m mRNA levels were reduced compared to parental fibroblasts.
HLA–F was expressed at similar levels in both cell types whilst
HLA-A and HLA-G expression was absent in stem cells.
Regarding the APM genes, TAP-1, TPN, LMP2 and RFX5
mRNA levels plummeted during the reprogramming process to
iPSCs. TAP-2, CLR and CIITA were expressed at very low levels
in both cell types. The chaperone molecules, CNX and ERp57,
and LMP7, had elevated mRNA levels in iPSCs versus fibroblasts.
Similar to hESC, no expression of HLA-G and MHC class II
molecules was observed. In short, iPSC show reduced MHC class
I expression with respect to its parental fibroblast line, suggesting
down-regulation of these genes during the cellular reprogramming
process.
Increase of MHC expression during the differentiation
process
To determine the effect of differentiation on MHC expression,
Shef-1 cell line was differentiated to embryoid bodies (EBs) and
MHC in Human Stem Cells
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expression of MHC and APM molecules on undifferentiated and
differentiated cells (Figure 2). EBs displayed significantly higher
expression of HLA-I classical molecule, HLA-B, and the non-
classical HLA-E and –F compared to the undifferentiated cells.
b2m showed the highest increase of 42 fold as a result of the
differentiation process. We proposed that a possible mechanism of
the MHC class-I up-regulation could be augmented expression
and/or the activation of the APM components. Expression of
TAP-1, TAP-2, TPN, ERp57, CNX, CLR and LMP7 genes was
induced in differentiated cells, although the level of up-regulation
varied. TAP-1 and TPN increased over 23 and 20 times
respectively, compared to undifferentiated Shef-1 cells. In contrast,
differentiation did not induce HLA-G, LMP-2, HLA-DR, and the
transcription factor CIITA mRNA expression. These data inferred
that these molecules might be repressed in a stable manner in
hESCs or regulated by other mechanisms. Similarly, the NT2 cell
line showed the highest up-regulation in HLA-B, b2m, TAP-1 and
TPN genes. However, in contrast to hESCs, RFX5 increased
slightly during the differentiation process with retinoic acid (RA).
In conclusion, b2m, TAP-1 and TPN increased significantly
during differentiation, suggesting that these genes could be
responsible for a limited HLA class I expression in undifferentiated
human stem cells.
Expression of NKG2D ligands in human stem cell lines
Downregulation of MHC class I molecules on cancer cells can
lead to their elimination by NK cells if the target cells express
ligands for stimulatory NK cell receptors, such as NKG2D ligands
(MICA-B, ULBPs 1–5). Analysis of the expression of NKG2D
ligands on the cell surface of Shef-1 and NT2 cell lines detected
only low expression of MICA proteins (Figure 3A). Quantitative
PCR analyses of NKG2D-L revealed that both cell lines express
MICA and MICB mRNA transcripts whilst ULBPs 1–3 were
absent or weakly expressed in these stem cell lines (Figure 3B,
C). The human embryonic kidney HEK-293T cell line, which
expressed all NKG2D-L mRNA transcripts was used as positive
control. These results indicated that expression of NKG2D-L in
stem cells could be regulated post-transcriptionally.
We further studied if differentiation was associated with
differences in the expression levels of NKG2D ligands. During
the differentiation process of hESC to embryoid bodies, most
NKG2D-L were maintained in EBs at levels similar to
undifferentiated cells, and only MICB expression was slightly
Figure 1. Expression of MHC class I and class II, and the molecules involved in the APM in undifferentiated Shef-1 and NT2 cell
lines. A) The expression of HLA class I and class II was determined by flow cytometry in undifferentiated Shef-1 and NT2 cell lines. The EBV-
transformed B cell line Pitout, which expresses class I and class II, was used as positive control. HLA class I and class II were stained with an anti-pan
HLA class I (anti-HLA-ABC mAb)-FITC and HLA-DR-PerCP respectively. Viable cells were gated using 7AAD staining. Thin lines show cells treated with
isotype control and black histograms represent positive cells. Similar results were obtained from four independent experiments. B) Quantitative-PCR
analysis of classical MHC class I molecules (HLA-A,–B and -C), non-classical MHC molecules (HLA-E,-F and –G), antigen processing molecules (TAP-1,
TAP-2, TPN, CNX, CLR, ERp57, LMP2, LMP7) and the transcription factors RFX5 and CIITA in undifferentiated Shef-1 and NT2 cells, compared to the
control, Pitout cell line. mRNA levels were normalized to GADPH mRNA. C) Quantitative-PCR analysis of the MHC genes and APM components in
iPSCs and parental IMR90 fibroblast line. The upper right histogram has shown the expression levels of the pluripotent transcription factors Nanog
and Oct-4 in fibroblast and iPSCs. mRNA levels were normalized to GADPH mRNA. The results of quantitative PCR are represented as means 6 SD
from triplicate experiments. * P,0.05.
doi:10.1371/journal.pone.0010192.g001
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teratocarcinoma cell line in vitro by the addition of RA to the
cultures for 3 weeks and compared the expression levels of
NKG2D-L between undifferentiated and differentiated cells
(Figure 3C). Treatment with RA significantly increased MICB
mRNA expression in a time dependent manner. However, the
increased MICB transcripts were not correlated with high levels of
MICB protein on cell surface (data not shown), suggesting
additional mechanisms of regulation in this molecule.
Human IMR90 fibroblasts, which were the source for the
iPSCs, expressed all NKG2D-L (Figure 3D) but only MICA and
MICB expression were detected by real-time RT-PCR in iPSCs,
suggesting down-regulation of these ligands during the repro-
gramming process to pluripotent stem cells.
Expression of MHC and APM genes is up-regulated by
TSA and 5-azaC
To examine the possibility that some MHC class I processing
pathway components were epigenetically regulated in hESCs, cells
were treated with the epigenetic inhibitors, Trichostatin A (TSA)
and 5-azacytidine (5aza-C). IFN-c, which was reported to induce
MHC class I and II expression, was used as control.
MHC class I expression was up-regulated in NT2 cells treated
with IFN-c and 5aza-C predominantly (Figure 4A), but the
expression of MHC class II was only increased by exposure to the
inhibitor of DNA methyltransferase, 5aza-C. Notably, the effects
of TSA and 5aza-C were not synergistic. These results suggested
that the absence of MHC class II expression might be due to DNA
methylation of these genes or the molecules involved in their
regulation.
The effects of epigenetic inhibitors on MHC class I expression
were investigated by quantitative real-time RT-PCR in Shef-1 cell
line (Figure 4B). Treatment with 5aza-C significantly increased
the expression of TAP-2 gene but only modestly augmented most
APM genes. The histone deacetylase inhibitor (HDACi), trichos-
tatin A (TSA), promoted acetylation of histones by inhibiting
HDAC and is generally associated with enhanced transcription.
Here, we showed that TSA treatment altered MHC class I
expression. HLA-B, b2m, TAP-2, TPN and LMP7 expression was
significantly enhanced after treatment with 100 nM of TSA.
Combined effects of both epigenetic inhibitors were only observed
in HLA-B and b2m genes. These results suggested that epigenetic
mechanisms may be involved in the regulation of genes required
for correct antigen processing and presentation of MHC class I
molecules on cell surface of hESCs.
While alone IFN-c-treatment did not significantly increase the
expression of the non-classical MHC class I molecule HLA-G,
cells treated with epigenetic inhibitors alone or in combination
significantly augmented HLA-G expression, inferring that epige-
netic modifications were necessary for the correct expression of
HLA-G. Similarly, MHC class II molecules (HLA-DRA) and the
essential transcription factor for its expression, CIITA, were
significantly induced after treatment with epigenetic modifiers. No
relevant changes in the expression of RFX5 were observed.
Previous studies in tumour cells have shown that the expression
of IFN-c-inducible genes can be enhanced by treatment with
epigenetic inhibitors. In our study, we observed that the combined
effects of 5aza-C and IFN-c slightly enhanced the expression of
HLA-B and HLA-G compared to cells treated with 5aza-C alone
(Figure 4B). The combination of 5aza-C plus IFN-c on the
CIITA gene exerted a greater than additive effect, suggesting that
demethylation of the CIITA promoter may be necessary for the
further induction by IFN-c.
Methylation of HLA-G, MHC-II and CIITA in hESCs
Methylation is one of the major epigenetic modifications that
repress transcription in vivo. The methylation state of the genes
implicated in the MHC expression (HLA class I and II molecules,
and APM components) was assessed with bisulfite modification of
isolated genomic DNA from undifferentiated stem cells and its
derivative cells. Most genes studied were not methylated in the
promoter region, indicating that the transcription of these genes in
Figure 2. Up-regulation of MHC genes during the differentiation process. Expression levels of the MHC genes and APM components were
analyzed by quantitative RT-PCR at different times during the differentiation process to EBs and neuronal precursors. Results are represented as fold
up-regulation for each gene in differentiated cells compared to their undifferentiated cells. The results of quantitative PCR are represented as means
6 SD from triplicate experiments. * P,0.05. Abbreviation; w: week; RA: Retinoic acid.
doi:10.1371/journal.pone.0010192.g002
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G, HLA-DR and CIITA genes were fully methylated. Profiles of
CpG methylation in the regulatory regions of these genes were
represented graphically in Figure 5. HLA-DR loci were
completely methylated at all 9 CpG sites analyzed in Shef-1 and
NT2 cells and this methylation status was maintained through the
differentiation process. In contrast, the control cell line Pitout
expressed MHC class II and displayed no methylation in the
promoter region. The transcription factor CIITA, which regulated
the expression of MHC class II molecules, was completely
methylated in Shef-1, NT2 cells, and neuronal progenitors,
although some CpG sites exhibited partial methylation in EBs
(Figure 5). HLA-G gene contained a CpG island around its
transcriptional start site. This region was partially methylated in
Shef-1 and EBs, and only 4 CpG sites were fully methylated
(region 2211 to 2272). NT2 and derivative cells exhibited full
methylation in all HLA-G CpG sites.
Results of bisulfite sequencing were confirmed by methylation
arrays (Figure S2, Table S1). The MHC class II genes (HLA-
DP, -DQ and –DR) and their transcription factor CIITA were
hypermethylated in hES and iPS cells (array signal $0.7, red)
whereas MHC class I and APM components were demethylated in
hES and iPS cells (array signal ,0.3, green). Some divergences
respects to bisulfite sequencing were observed in HLA-G and
TAP-1, probably due to the different regions analyzed by both
methods. The specific probe for HLA-G gene overlapped a region
(2497 bp) far from the transcription start, and not include CpG
sites.
As we show by methylation arrays (Figure S2), profiles of
methylation were very similar between induced pluripotency and
human embryonic stem cells. Thus, the absence of MHC class II
and HLA-G expression in hESC and iPSC may be due to DNA
methylation of these genes in combination with the transcription
factor, CIITA.
H3-K4 and H3-K9 methylation profiles in hES and iPS cells
Posttranslational modifications of the amino-terminal tails of
core histones also contribute to regulation of gene expression. To
determine whether histone modifications regulate MHC tran-
scription during the differentiation process, we performed ChIP
assays using antibodies against the marks H3K4me3 (active) and
H3K9me3 (repressive). H3K4 trimethylation at the HLA-B
promoter was higher in EBs than in undifferentiated Shef-1 cells
(Figure 6A), whereas H3K9me3 was similar in both cell types.
Similarly, the level of H3K4 trimethylation in b2m gene was 60
fold higher in EBs than in Shef-1 cells, and corresponded to the
Figure 3. Expression of NKG2D ligands for natural killer cells in undifferentiated and differentiated human stem cells. (A) The
expression of NKG2D ligands was analyzed in undifferentiated Shef-1 and NT2 cells by flow cytometry using monoclonal antibodies against MICA,
MICB, ULBP-1, ULBP-2 and ULBP-3 (1 mg of mAb for sample) followed by FITC-conjugated goat anti-mouse as secondary reagent. Dead cells were
excluded by staining with 7AAD. Isotype controls were shown by thin lines and black histograms represented expression of each specific antibody.
The HEK-293T cell line was used as positive control. All experiments were performed at least two - three times with similar results. Transcript levels of
NKG2D ligands were analyzed by quantitative RT-PCR in undifferentiated human stem cells and during the differentiation process. Undifferentiated
Shef-1 (B) and NT2 (C) cells were differentiated to EBs and neuronal precursors, respectively and the expression for NKG2D ligands was analyzed. The
induced pluripotent stem cell line, MSUH-002 (D) was compared to parental fibroblast line. The HEK-293T cell line, which expresses mRNA of all the
NKG2D ligands, was used as positive control. Histograms represented the relative expression of each gene normalized against the housekeeping
gene GADPH. Data are represented as mean 6 SD of three independent experiments. * P,0.05. Abbreviation; w: week; RA: Retinoic acid.
doi:10.1371/journal.pone.0010192.g003
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the histone modification H3K4me3 facilitated chromatin relaxa-
tion in HLA-B and b2m genes during the differentiation process
and allowed its expression. CIITA gene also showed high levels of
H3K4me3 in EBs, suggesting a possible increased mRNA
transcript level in these cells. In respect to the APM genes,
H3K4me3 of TAP-1, TAP-2 and TPN genes was similar in
undifferentiated and differentiated cells. However, the repressive
mark was significantly higher on TPN in Shef-1 cells than in EBs,
and corresponded to undetectable TPN levels in undifferentiated
Figure 4. Epigenetic treatments enhanced MHC class I and II expression in undifferentiated embryonic stem cells. A) MHC class I and II
cell-surface expression in NT2 cells. Cells were treated with IFN-c (100 U/ml for 24 h), 5aza-C (2 mM for 48 h), TSA (100 nM for 24 h) or a combination
of both. After 24 h in culture, cells were stained with specific monoclonal antibodies for MHC class I and II or isotype controls and analyzed by flow
cytometry. Isotype controls were shown by thin lines and black histograms represented expression detected by each specific antibody. The
proportions of living, dead and apoptotic cells were determined with 7AAD and Annexin V-FITC. Similar results were obtained from three
independent experiments. B) Quantitative PCR analysis of mRNA levels of MHC class I, class II and APM components in Shef-1 cells treated with
epigenetic agents. Cells were cultured with 5aza-C (10 mM), TSA (100 nM) and IFN-c (100 U/ml) alone, or in combination for 6 hours, and maintained
for additional 24 h before RNA extraction. The histograms represented the fold increase of each gene after treatment compared to the basal level of
untreated undifferentiated Shef-1 cells. Results were mean 6 SD from three independent cultures. * P,0.05.
doi:10.1371/journal.pone.0010192.g004
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modification may hinder their transcription by maintaining a
compact state of chromatin in undifferentiated cells,. The limited
HLA-DR and RFX5 expression during the differentiation process
may reflect the high H3K9me3 in the promoter region in EBs. We
did not find any mark in the promoter region of the non-classical
MHC class I genes (HLA-E, -F and –G) (data not shown),
suggesting that other histone modifications or mechanisms were
involved in their regulation.
Histone modifications in fibroblasts on HLA-B, b2m, and some
APM genes exhibited activation marks congruent with their
expression (Figure 6B). In contrast to hESCs, iPSCs exhibited
the repressive mark H3K9me3 at the HLA-B promoter, which
correlated with the reduced expression of this gene. Histone
modifications in TPN gene were similar between iPSCs and
hESCs, and high levels of both marks were observed, consistent
with its repression in undifferentiated stem cells. However,
H3K9me3 was higher in the promoter region of HLA-DR,
CIITA and RFX5 in iPSCs than in hESCs.
Thus, HLA-B, b2m, HLA-DR, TPN and CIITA might be
regulated in hESCs by histone modifications, such as H3K4me3
and H3K9me3 marks. Additionally, we verified that HLA-B,
TPN, HLA-DR, CIITA and RFX5 acquired repressive marks
which suggested chromatin was remodelled during the repro-
gramming process from human somatic cells to induced
pluripotency stem cells.
Discussion
Overcoming the immunological barriers to the stem cell
transplantation is one of the most important clinical challenges,
and will change the future of regenerative medicine and cellular
therapy. Therefore, it is critical to understand the immunogenicity
of hESCs, and the necessary modifications to induce acceptance of
these cells by the patient’s immune system. Several approaches
had been proposed to overcome graft rejection, such as
development of hESCs banks, nuclear transfer, or the creation
of a universal stem cell line [29]. The iPSCs technology potentially
could overcome two important problems associated with human
hESCs: ethical problems based on the use of human embryos and
immune rejection after transplantation [30], although little is
known so far about the immunogenicity of these new pluripotent
stem cells.
In this report, we demonstrated that hESCs expressed low levels
of classical HLA-class I and absence of HLA-class II molecules on
the cell surface. Analogous expression levels were observed in
human iPSCs, suggesting down-regulation of these molecules
during the cellular reprogramming process from human adult
fibroblast. Furthermore, pluripotent stem cells (Shef-1, NT2 and
MSUH-002 cell lines) show absent or reduced expression of b2-
microglobulin light chain, which could limit the expression of the
MHC class I trimeric molecule on the cell surface. Similarly with
tumour and trophoblast cells, the absence of MHC class I
Figure 5. Methylation profile of HLA-G, CIITA and HLA-DRA promoter regions in undifferentiated and differentiated cells by
bisulfite sequencing analysis. The upper panels displayed a schematic map of each promoter region studied. The position of each CpG
dinucleotide was depicted with thin vertical lines. Transcriptional start site is indicated by a thick vertical line and the +1 position indicated the
translation start site. Arrows indicated the amplified region by RT-PCR for bisulfite sequencing analysis. In HLA-G, the horizontal gray line marked the
CpG island. Ten clones were sequenced for each sample and each circle represented the average methylation for each CpG dinucleotide (open circle:
100% unmethylated, black circle: $50% CpG methylated, gray circle: ,50% CpG methylated). The numbers denoted the position of each CpG site
studied. Pitout cell line, which express MHC class I and II was used as control.
doi:10.1371/journal.pone.0010192.g005
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cells.
We hypothesized that low levels of MHC class I molecules could
be due to defects in the APM components in stem cells. Expression
of TAP-1, TAP-2 and TPN molecules, which are implicated in the
transport and load of peptides onto MHC class I molecules, was
weakly detected in embryonic and induced pluripotent stem cells.
Unexpectedly, the NT2 teratocarcinoma cell line shows a low
expression of TAP-1 and TAP-2, but express tapasin at normal
levels. The lack of the TAP-1/TAP-2 complex in hESCs implied
that the pool of endogenous peptides can not bind to MHC class I
dimers, and inhibited the MHC class I heavy and light chain
complexes from leaving the endoplasmic reticulum. TAP-1
knockout mice show significantly reduced levels of MHC class I
surface expression [31]. In addition, the chaperones ERp57, CNX
and the immunoproteasome component LMP7 were commonly
expressed at high levels by all stem cell lines, indicating that the
folding of MHC molecules and generation of antigenic peptides in
these cells were not damaged. Taken together, our results
confirmed that pluripotent stem cells were partially defective in
their ability to process and present MHC class I molecules on the
cell surface. These results are in line with a previous report which
show that the HS293 hESC line lack the expression of some APM
components [32].
During the differentiation process to EBs, most HLA class I
molecules and APM components except HLA-G and LMP2
increased significantly compared to undifferentiated Shef-1 cells.
Additionally, b2m protein, TAP-1 and TPN increased strongly
upon differentiation, suggesting that the up-regulation of MHC
class I in differentiated cells might be a consequence of the
increased expression of these genes during the differentiation
process. However, no changes in the expression of MHC class II
and CIITA were observed. Thus, increased expression of MHC
class I in differentiated stem cells may lead to the recognition and
elimination by T cells, representing the most important barrier for
transplantation of pluripotent stem-cell-derived allografts.
That is the first time that NKG2D ligands were analyzed in
human stem cells. Expression of MICA and MICB genes at RNA
Figure 6. Methylation of histones H3-K4 and H3-K9 regulated MHC expression in hES and iPS cells. Levels of the trimethylation H3-K4
(active mark, H3K4me3) and H3-K9 (repressive mark, H3K9me3) were determined at selected regions of MHC genes and APM components in: A)
undifferentiated Shef-1 cells (white columns), or embryoid bodies (EBs) (black columns) formed after 10–15 d differentiation in culture and B) IMR90
human fibroblast (light gray columns) and MSUH-002 cells (dark gray columns). Cells were subjected to ChIP assay using antibodies against H3K4me3
and H3K9me3, and analyzed by quantitative PCR with specific primers for each gene. Normal rabbit IgG was used as negative control for the
specificity of the immunoprecipitation (IP). As a positive control, aliquots of chromatin fragments obtained before IP were also subjected to Q-PCR
analysis (Input). Immunoprecipitated DNA associated with a given histone modification was normalized to a 100-fold dilution of input chromatin.
Data are expressed as fold enrichment of each modification compared to negative control antibody (normal rabbit IgG), and represented mean 6 SD
of two representative experiments with similar results (*P,0.05: **P,0.01).
doi:10.1371/journal.pone.0010192.g006
MHC in Human Stem Cells
PLoS ONE | www.plosone.org 8 April 2010 | Volume 5 | Issue 4 | e10192level was found in Shef-1 and NT2 cell lines and maintained
during the differentiation to EBs and neuronal progenitors,
respectively. ULBP proteins were weakly expressed and only
slightly increased during the differentiation with RA. iPSCs
showed a similar pattern of NKG2D-L expression, although it
was not possible in this study to determine the protein level on the
cell surface. Human stem cells with MICA and MICB expression
may be recognized and lyzed by NK cells even in the presence of
inhibitory MHC class I molecules. Previous studies have reported
that mouse embryonic stem cells are resistant to lysis by NK cells
[33] while Dressel et al [34] showed that susceptibility to lysis by
NK cells mediated by NKG2D ligands is a common feature of
pluripotent murine stem cells. Differences between these studies
may be explained by differences in the activation status of the NK
cells. Recently, Di Tomaso et al [35] have demonstrated that
cancer stem cells (CSCs) isolated from human tumours were
negative for NKG2D ligands. Treatment of CSCs with the
demethylating agent, 5aza-C, restored the expression of these
molecules, and led to their recognition and lysis by NK cells.
Nevertheless, in our study, no cell surface expression of
NKG2D-L was detected on Shef-1 and NT2 cell line except low
levels of MICA. These results suggest that NKG2D ligands might
be regulated at the post-transcriptional level in stem cells. Several
microRNAs have suppressed the expression of MICA and MICB
proteins below a certain threshold and facilitated an acute up-
regulation during cellular stress [36,37]. Furthermore, MICB has a
shorter half-life at the plasma membrane than MHC molecules
[38]. MICB expression depends on its recycling in trans-Golgi
network and late endosome-related compartments as well as
shedding into the extracellular medium.
Expression of NKG2D-L at RNA level but no protein
expression was detected on the cell surface of trophoblast cells
[39,40], showing a permanent shedding of these ligands from
trophoblast cells mediating the maternal-fetal tolerance. Addition-
al studies have confirmed that exosomes bearing NKG2D-L are
released by human placenta and tumour cells and induce down-
regulation of the NKG2D receptor on NK and CD8+ T cells
which inhibited their cytolytic capability [41,42]. Our data
suggested that human stem cells may use similar mechanisms to
evade the recognition by NK cells and contribute to the immune-
privileged properties of these cells. Further studies are warranted
to verify the role and regulation of NKG2D ligands in hESC.
Epigenetic modifications, such as hypermethylation of promoter
regions or histone modifications may regulate the expression of
MHC class I and II, and APM molecules in human pluripotent
stem cells. To confirm this, we cultured hESCs in vitro with 5aza-C
and TSA, showing that epigenetic mechanisms alter the expression
of all APM components involved in the antigen processing and
presentation. We observed that expression of HLA-DR and
CIITA was only induced by the treatment with epigenetic agents
but not during the differentiation. These data suggested that direct
or indirect epigenetic modifications were required to restore their
expression. Absence of MHC class II molecules in hESCs was
associated with hypermethylation in the CIITA promoter region,
in addition to methylation in the promoter region of the HLA-
DRA gene. Moreover, methylation of CIITA may be at least
partially responsible for the low levels of MHC class I expression,
as transfection of trophoblast cells with CIITA has restored MHC
class I expression [43]. Additionally, HLA-G promoter was fully
methylated in 4 CpG sites in hESCs and EBs, so this region could
be directly implicated in the regulation of HLA-G. In agreement
with our results, it has been recently reported that the 4 CpG sites
in the HLA-G promoter region contained a hypoxia response
element (HRE) that remained completely methylated in ovarian
cancer cell lines [44]. Thus, methylation of HLA-DR and HLA-G
promoters in human stem cells contributed to the restricted
expression of these genes in somatic cells.
Modifications of histones proteins are responsible for a ‘‘histone
code’’ that epigenetically regulates chromatin and gene expression
[45]. We have analyzed some of these histone marks to determine
whether they are involved in the regulation of APM components.
H3K4me3, a histone mark that facilitates the binding of
transcription factors, was present at high levels in HLA-B and
b2m gene promoters in EBs in comparison to undifferentiated
Shef-1 cells. Although no H3K9me3 was observed in undifferen-
tiated cells, other repressive marks not analyzed here could be
involved in the repression of these genes. Absence of TPN
expression in undifferentiated hESCs might be due to the presence
of the repression mark H3K9me3, which is present at lower levels
in differentiated cells. Tapasin is involved in the stabilization of
TAP-1/2 complex and peptide loading in MHC class-I molecules,
and could act as a limiting factor in the expression of these
molecules in hES cells. Furthermore, this repressive mark was
acquired when human IMR90 fibroblasts were reprogrammed
into iPSCs, indicating that epigenetic changes in MHC genes
occur during the cellular reprogramming process.
Absence of MHC class II induction in EBs can be associated
with H3K9me3 in HLA-DR, although we demonstrated above
that other mechanisms such as DNA methylation can also
participate in their repression. The active mark, H3K4me3, was
present in CIITA gene in EBs and facilitated the transcription
process during differentiation. However, we now know that the
CIITA promoter was methylated in human stem cells. Addi-
tionally, the HLA-DR gene and the transcription factors CIITA
and RFX5 exhibited high levels of H3K9me3 in iPSCs. These
data indicated that these genes could be silenced during the
reprogramming process by repressive histone modifications in
addition to DNA methylation. In fact, it has been described
previously that trimethylation of H3K9 is associated with DNA
methylation [46]. This is the first time that histone modifications
(H3K4me3 and H3K9me3) were described in APM components
and implicated in the low expression of MHC class-I or absence
of MHC class-II molecules in hESCs. Moreover, the analogous
distribution of histone modifications between hESC and iPSCs
suggest that changes detected in regulatory regions of MHC
genes are indicative of remodelling chromatin on APM
promoters to acquire an epigenetic state characteristic of
pluripotent cells. Likewise, murine iPSCs were highly similar in
their epigenetic state to ES cells, showing that transcription
factor-induced reprogramming leads to the global reversion of
the somatic epigenome into an ES-like state [47]. Further studies
with other histone modifications will be necessary to elucidate the
complete epigenetic regulation of these genes in pluripotent stem
cells.
In short, the lack or down-regulation of MHC molecules in
hESCs is due to absence of some APM mRNA transcription. The
differentiation process augments mRNA transcription of APM
components which yield an increase of MHC class I on cell
surface. This process is regulated by modifications in chromatin
remodelling, mainly H3K4me3 in HLA-B, and b2m, as well as
H3K9me3 in TPN gene, respectively. Moreover, DNA methyl-
ation profile matched the absence of MHC class-II and the
tolerogenic molecule HLA-G expression in undifferentiated and
differentiated hES cells. We conclude that epigenetic modifications
regulate MHC class I and class II expression in hESCs and iPSCs,
similar to trophoblast and tumour cells. Reduced MHC class I and
class II expression in hESCs and iPSCs can limit their recognition
by the immune response against these cells. The knowledge of
MHC in Human Stem Cells
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induce tolerance and improve acceptance of stem cell allografts.
Materials and Methods
Cell lines
The lymphoblastic cell line PITOUT was grown in RPMI
medium supplemented with 10% heat-inactivated fetal bovine
serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin and
100 mg/ml streptomycin. HEK-293T (human embryonic kidney
293T cells) cell lines were maintained in supplemented DMEM
medium.
Embryonic stem cells culture, differentiation and
treatment
The hES cell line, Shef-1 [48] was maintained in hESCs
medium, Knock-Out DMEM medium supplemented with 20%
Knock-Out Serum Replacement on inactivated mouse embryonic
fibroblast (MEF) as previously described [49,50]. For differentia-
tion to embryoid bodies (EBs), hES Shef-1 colonies were cultured
in suspension in hESCs medium without bFGF-2 for 10–15 days.
The human embryonal carcinoma cell line NTera2 clone D1
(NT2) was cultured in DMEM medium +10% FBS and differen-
tiated to neuronal progenitors with 10 mM all-trans-retinoic acid
(Sigma-Aldrich) for 3–4 weeks as previously described [51].
Culture and characterization of Shef-1 and NT2 cell lines was
detailed in Methods S1 and Figure S1.
Shef-1 and NT2 cells were cultured in ES medium supple-
mented with 5-Aza-Cytidine (5azaC) and/or Trichostatin A (TSA)
(Sigma-Aldrich) at indicated concentrations. Subsequently, cells
were cultured in fresh medium for 24 h before RNA extraction. As
control, Interferon-c was used at 100 U/ml.
Induced Pluripotent stem cells
DNA and RNA from the human induced Pluripotent Stem Cell
(iPSC) Line, MSUH-002, were kindly gifted by Professor J. Cibelly
at the University of Michigan University. These stem cells were
produced from IMR90 cells as previously described [28]. Briefly,
viral vectors were packed in HEK-293T cells. The resulting viral
particles were concentrated by ultracentrifugation and the viral
transductions were performed in hESCs media. iPSCs colonies
were manually detached and expanded as individual clones in the
same media.
Immunofluorescence
hES cells were fixed with 4% paraformaldehyde and stained
with the primary antibodies SSEA-3 (1:40), SSEA-1 (1:10) and
TRA1-60 (1:100) (kindly gifted by Professor Moore, Sheffield, UK)
overnight at 4uC followed by incubation with FITC-conjugated
second antibodies for 1 h.
Reverse transcription-PCR and real-time RT-PCR
Total RNA was isolated using the RNeasy kit (Qiagen,
Valencia, CA) according to the manufacturer’s instructions and
reverse transcribed using the iScriptTM cDNA Synthesis kit
(BioRad, Hercules, CA). Real-time PCR assay was performed in
20 ml of SYBR Green Super Mix (Bio-Rad) using a MyiQ Single-
Color Real-Time PCR Detection System (Bio-Rad). DNA was
denatured at 95uC for 30 seconds, annealing at 60uC for 1 min,
elongation at 72uC for 1 min and extension at 72uC for 5 min.
Primers used are reported in Table S2. Fold changes in transcript
levels were calculated using threshold cycle (Ct) values standard-
ized to GAPDH, which was used as the endogenous control. All
samples were run in triplicate and at least two independent
experiments were carried out.
Flow cytometry analysis
hES colonies were harvested with 0.1% collagenase IV
(Invitrogen, CA), dissociated into single cells and stained with
the monoclonal antibodies FITC-conjugated anti-pan HLA class I
(anti-HLA-ABC mAb) and PerCP-conjugated HLA-DR (BD
Biosciences). Analysis was carried out in a FACScan Cytometer
(Becton Dickinson). Antibodies against NKG2D ligands (MICA,
MICB, ULBP 1–3) (R&D Systems) were used at 1 mg/ml and
FITC goat anti-mouse (eBioscience) was used as secondary
antibody. The proportions of living, dead and apoptotic cells
were determined with 7AAD and the Annexin V-FITC apoptosis
detection kit (Immunostep Inc; Spain).
DNA methylation array
Methylation was assessed at 1,505 CpG sites using Illumina
Goldengate Methylation Arrays and analyzed as we previously
described [48]. Details are reported in Methods S1.
Bisulfite modification
DNA methylation was determined by PCR analysis after
bisulfite modification of the DNA. Genomic DNA was purified
using the DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA)
according to manufacturer’s recommendations. DNA bisulfite
modification was performed using the EZ-DNA Methylation kit
(Zymo Research, CA) and the DNA was amplified using specific
primers designed with the Methyl Primer Express SoftwareH
(Applied Biosystems). Primers were shown in Table S3. PCR
products were cloned into pGEM-T Easy Vector System II
(Promega, Madison, WI) and DNA plasmids purified with the
QIAprep Spin Miniprep Kit (Qiagen). In each case, ten
independent clones were automatically sequenced to determine
their degree of methylation.
Chromatin immunoprecipitation (ChIP) assay
Chromatin immunoprecipitation assays using 0.5-1610
6 cells
per sample were performed as previously described [52] with the
anti-trymethylated H3K4 and H3K9 (Upstate Biotechnologie-
s.Inc) antibodies. Normal IgG was used as negative control. In
brief, fixed cells with 1% formaldehyde were lysed in SDS-lysis
buffer (1%SDS, 10 mM EDTA, 50 mM Tris-HCl pH 8.1) and
sonicated. The shared chromatin were diluted into ChIP dilution
buffer (0,01% SDS, 1,1% Triton X100, 1,2 mM EDTA, 16,7 mM
Tris-HCl pH 8,1, 167 mM NaCl) and incubated with the
antibodies overnight at 4uC. Antibody-chromatin complexes were
precipitated with Salmon Sperm DNA/Protein A-Agarose beads
(Upstate Biotechnologies), washed and eluted from the beads using
elution buffer (1% SDS, 0.1 M Na HCO3). After cross-link
reversal and proteinase K treatment, DNA was extracted with
phenol-chloroform and ethanol precipitated. Immunoprecipitated
DNA was analyzed in triplicate by real-time PCR from 1 mlo f
eluted DNA. Primers for each promoter were listed in Table S4.
Aliquots of chromatin obtained before immunoprecipitation were
analyzed as input control. Results are presented as fold enrichment
of precipitated DNA associated with a given histone modification,
relative to a 1/100 dilution of input chromatin.
Statistics
Statistics were calculated using SPSS Student version 14.0
software. Student’s t test was used for statistical analysis. A P value
of ,0.05 was considered significant.
MHC in Human Stem Cells
PLoS ONE | www.plosone.org 10 April 2010 | Volume 5 | Issue 4 | e10192Supporting Information
Methods S1
Found at: doi:10.1371/journal.pone.0010192.s001 (0.03 MB
DOC)
Figure S1 Culture and characterization of human embryonic
stem cell line Shef-1 and the human carcinoma cell line NTera2
and differentiated cells. A) Culture of Shef-1 hES cell line and
differentiation to embryoid bodyes (EBs). Shef-1 cells were grown
in mouse embryonal fibroblast (MEFs) in gelatine-coated dishes in
complete hESC medium with bFGF-2 (a). To differentiate to EBs
(c), colonies were detached from MEFs and culture in suspension
without bFGF-2 for 15 days. Panels b and d displayed hESC and
EBs from Shef-1 cells respectively, at high magnification. B)
Immunofluorescence analysis of specific cell-surface antigens,
SSEA-1, SSEA-3 and TRA1-60 in Shef-1 hESC. Undifferentiated
cells were strongly positive for SSEA-3 and TRA1-60 and only
differentiated cells were stained by SSEA-1 antibodies. C)
Induction of neuronal morphology in NT2 cell line. Undifferen-
tiated cells (a) were treated with retinoic acid (RA) for 3–4 weeks.
Samples were taken 1 week (b) and 3 weeks (c,d) and neuronal
progenitors were observed. D) RT-PCR analysis of in vitro
differentiated hESCs to EBs for detection of expressed genes of the
three embryonic germ layers, enolase (mesoderm), amylase
(endoderm) and neurofilament (ectoderm) and pluripitency genes
(Nanog and Oct-4). E) RT-PCR analysis during the differentiation
process of NT2 cell line to neuronal progenitors, Differentiated
cells express well-characterized neuronal markers such as Tau or
NeuroD whilst Nestin, a typical neuroectodermal marker, was
downregulated by RA treatment. The transcription factors Nanog
and Oct-4 were lost after 1 week in culture showing a right process
of neural differentiation.
Found at: doi:10.1371/journal.pone.0010192.s002 (5.40 MB TIF)
Figure S2 Methylation profiles of MHC genes and APM
components. Methylation profiles of HLA class I, class II, antigen
processing machinery (APM) genes and transcription factors (TF)
involved in MHC regulation in hESCs, NT2 cell line, iPSCs and
IMR90 fibroblast were obtained by Illumina arrays. Cluster
analysis was based on correlation of methylation profiles of MHC
and PM genes. The methylation levels vary from fully methylated
(red) to fully unmethylated (green) sequences.
Found at: doi:10.1371/journal.pone.0010192.s003 (0.92 MB
TIF)
Table S1 Classification of MHC genes according to their
promoter methylation status in hESCs Shef-1, NT2 cell line,
iPSC cell line and human fibroblast IMR90. The classification
criteria are described in the Methods S1.
Found at: doi:10.1371/journal.pone.0010192.s004 (0.07 MB
XLS)
Table S2 Primers used for real-time RT-PCR.
Found at: doi:10.1371/journal.pone.0010192.s005 (0.06 MB
DOC)
Table S3 Primers used for bisulfite sequencing.
Found at: doi:10.1371/journal.pone.0010192.s006 (0.04 MB
DOC)
Table S4 Primers used for Chromatin Immunoprecipitation
(ChIP) assay.
Found at: doi:10.1371/journal.pone.0010192.s007 (0.04 MB
DOC)
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